These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24527792)

  • 1. Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors.
    Liscio P; Carotti A; Asciutti S; Karlberg T; Bellocchi D; Llacuna L; Macchiarulo A; Aaronson SA; Schüler H; Pellicciari R; Camaioni E
    J Med Chem; 2014 Mar; 57(6):2807-12. PubMed ID: 24527792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Synthesis of Poly Heterocyclic Compounds Containing [1,2,4]triazolo and [1,2,3,4]tetrazolo Moieties and their DFT Study as Expected Anti-cancer Reagents.
    Abdelrehim EM; El-Sayed DS
    Curr Org Synth; 2020; 17(3):211-223. PubMed ID: 32101129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
    Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HAV activity of some newly synthesized triazolo[4,3-b]pyridazines.
    Shamroukh AH; Ali MA
    Arch Pharm (Weinheim); 2008 Apr; 341(4):223-30. PubMed ID: 18214848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,2-
    Morgenstern O; Giesen U; Garn T; Freitag M; Schmidt K; Großmann A; Trettin A; Thämlitz N; Lemmerhirt C
    Pharmazie; 2024 Aug; 79(7):130-145. PubMed ID: 39152559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure elucidation of 2,3,5,6,7,8-hexahydro-1 H-[1,2,4]triazolo[1,2-a]pyridazine-1-thione, 3,3-disubstituted and 2-substituted derivatives and evaluation of their inhibitory activity against inducible nitric oxide synthase.
    Schulz U; Freitag M; Schmidt K; Witetschek M; Polzin M; Morgenstern O
    Pharmazie; 2014 Oct; 69(10):731-44. PubMed ID: 25985562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.
    Kumpan K; Nathubhai A; Zhang C; Wood PJ; Lloyd MD; Thompson AS; Haikarainen T; Lehtiö L; Threadgill MD
    Bioorg Med Chem; 2015 Jul; 23(13):3013-32. PubMed ID: 26026769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
    Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
    J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
    Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
    Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of isoquinolin-1(2
    Yao H; Wang Y; Jiangwen M; Peng Y; Wang Z
    Pharmazie; 2021 Apr; 76(4):132-137. PubMed ID: 33849696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
    Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
    Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.
    Shultz MD; Kirby CA; Stams T; Chin DN; Blank J; Charlat O; Cheng H; Cheung A; Cong F; Feng Y; Fortin PD; Hood T; Tyagi V; Xu M; Zhang B; Shao W
    J Med Chem; 2012 Feb; 55(3):1127-36. PubMed ID: 22260203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
    Albright JD; Moran DB; Wright WB; Collins JB; Beer B; Lippa AS; Greenblatt EN
    J Med Chem; 1981 May; 24(5):592-600. PubMed ID: 6113284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors.
    Tang PC; Feng J; Huang L; Xu Z; Cheng L; Zhang X; Zhang L; Hu B
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6437-40. PubMed ID: 19815412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
    Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
    Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
    Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
    Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
    Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel binding mode of a potent and selective tankyrase inhibitor.
    Gunaydin H; Gu Y; Huang X
    PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.